

Table S1. Adjusted hazard ratio by quintiles of baseline urine NGAL concentration after excluding patients with history of cardiovascular disease (heart failure, MI, stroke and PAD)

| | | Urine NGAL concentration (ng/ml) | | | | |
|---|------------------------------------|--|------------------|------------------|------------------|------------------|
| | | ≤6.9 | >6.9 - ≤12.9 | >12.9 - ≤22.6 | >22.6 - ≤49.5 | >49.5 |
| Heart failure events | No. of events | 12 | 27 | 35 | 36 | 52 |
| | Total number of years of follow-up | 2458.0 | 2477.8 | 2249.5 | 2358.5 | 2037.1 |
| | Event rates (per 100 person-years) | 0.49 | 1.09 | 1.56 | 1.53 | 2.55 |
| | Adjusted* Hazard ratio (95%CI) | Ref | 2.12 (1.04-4.34) | 2.44 (1.29-4.98) | 1.81 (0.86-3.81) | 2.12 (0.99-4.50) |
| | Adjusted* Hazard ratio (95%CI) | 1.003 (0.987 - 1.020) per 0.1 increase in log urine NGAL | | | | |
| Ischemic atherosclerotic events (composite of MI, PAD, ischemic stroke) | No. of events | 17 | 28 | 34 | 25 | 49 |
| | Total number of years of follow-up | 2438.3 | 2473.7 | 2237.8 | 2375.3 | 2069.3 |
| | Event rates (per 100 person-years) | 0.70 | 1.13 | 1.52 | 1.05 | 2.37 |
| | Adjusted* Hazard ratio (95%CI) | Ref | 1.57 (0.85-2.90) | 2.14 (1.15-3.99) | 1.45 (0.74-2.85) | 2.16 (1.27-4.82) |
| | Adjusted* Hazard ratio (95%CI) | 1.019 (1.003 - 1.035) per 0.1 increase in log urine NGAL | | | | |
| Deaths from all-causes | No. of events | 23 | 42 | 57 | 37 | 50 |
| | Total number of years of follow-up | 2585.5 | 2635.9 | 2421.8 | 2574.2 | 2315.0 |
| | Event rates (per 100 person-years) | 0.89 | 1.59 | 2.35 | 1.44 | 2.16 |
| | Adjusted* Hazard ratio (95%CI) | Ref | 1.51 (0.90-2.54) | 1.98 (1.18-3.33) | 1.04 (0.59-1.85) | 1.16 (0.64-2.09) |
| | Adjusted* Hazard ratio (95%CI) | 0.995 (0.981 - 1.009) per 0.1 increase in log urine NGAL | | | | |

*Adjusted for age, sex, race/ethnicity, estimated glomerular filtration rate , 24-hour urine albumin, diabetes mellitus, smoking status, blood pressure, body mass index, LDL cholesterol, HDL cholesterol, use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone receptor antagonists, statin and antiplatelet agents